Fate Therapeutics, Inc.

Fate reported first-quarter revenue of $1.9 million, flat versus the prior two quarters, tied to research funding under the Ono Pharmaceutical collaboration. R&D expense was $32.1 million, essentially flat sequentially; G&A rose 16% sequentially to $20.9 million; total operating expenses were $53 million, including $11 million of noncash share-based compensation. Net loss was $48 million, or $0.47 per share, and the company recorded a noncash $1.4 million nonoperating loss from the change in fair value of contingent MSK milestone payments. Cash, cash equivalents and investments were approximately $391 million at quarter end after the $80 million underwritten offering and $20 million concurrent private placement; full-year GAAP operating expenses are expected to be $215 million to $230 million, and year-end cash is expected to be more than $270 million.

Scott Wolchko focused on the shift in strategy toward autoimmunity and off-the-shelf cell therapy, arguing that safety, convenience, accessibility, and the ability to add on to standard regimens could make the programs differentiated. He repeatedly emphasized that conditioning chemotherapy is a barrier in autoimmunity and said Fate wants to move toward regimens that look more like standard community treatment rather than oncology-style hospitalization. His tone was confident and program-driven, with several mentions of expected second-half-2024 milestones.

Ed Dulac said the company is in a strong financial position, ending the quarter with about $391 million in cash, cash equivalents and investments after the March financing. He quantified first-quarter spending at $32.1 million in R&D, $20.9 million in G&A, and $53 million in total operating expenses, plus a $1.4 million noncash fair-value loss tied to the MSK contingent milestone liability. He also guided to full-year GAAP operating expenses of $215 million to $230 million and said year-end cash and investments should be more than $270 million, while noting quarterly cash burn has been roughly $37 million to $38 million and could move toward about $40 million as development activity increases.

Analysts pressed management on whether FT819 could work with single-agent cytoxan, and Wolchko said the company believes its bendamustine experience supports an IND amendment adding cytoxan-only conditioning. Questions also focused on FT522 without lymphodepletion; management said the early no-conditioning cohort will help show whether ADR can maintain activity and persistence in an intact immune compartment. Several analysts asked about competition from T-cell engagers and bispecifics, and Wolchko acknowledged the category’s disruptive potential but said Fate is designing its autoimmune programs to compete on safety, add-on use with standard care, and community accessibility as much as on efficacy.